Neoadjuvant therapy and bladder substitute for invasive bladder cancer: 20 years experience at Tohoku University
Senji Hoshi, Kenichi Suzuki(Tohoku University), Katsuko Sato(Tohoku University), Chikara Οhyama(Hirosaki University), Makoto Satoh(William S. Middleton Memorial Veterans Hospital), Takashige Namima(Japan Organization of Occupational Health and Safety), Seiichi Orikasa(Tohoku University), K. Yoshikawa(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), SEIICHI TOYODA(Tohoku University), Seiichi Saito(Hokkaido University)
Cited by 5
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253
Role of Respiratory Motor Output in Within-Breath Modulation of Muscle Sympathetic Nerve Activity in Humans
|Circulation Research|1999|142
Plasma Membrane-associated Sialidase Is Up-regulated in Renal Cell Carcinoma and Promotes Interleukin-6-induced Apoptosis Suppression and Cell Motility
|Journal of Biological Chemistry|2006|116